Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bicarbonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OR51E2 | Q9H255 | 2/20 | 0.67 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.67 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.67 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | GABRR1 | P24046 | 6/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 5/20 | 0.39 |
| ▸ | BLM | P54132 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | GABRR2 | P28476 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.39 |
| ▸ | GABRR3 | A8MPY1 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
| ▸ | GABRD | O14764 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL2427929 | 1.00 | — | — | |
| Glycine SCHEMBL8608021 | 0.86 | GLRA1 (0.91) | OR51E2GLRA1SLC6A9CA1CA2 | |
| Glycine SCHEMBL219254 | 0.86 | — | — | |
| Carbamic Acid SCHEMBL27817216 | 0.86 | — | — | |
| Glycine SCHEMBL29129757 | 0.86 | — | — | |
| Hydrogen Peroxide SCHEMBL4288872 | 0.84 | — | — | |
| Acetic Acid SCHEMBL1140278 | 0.82 | — | — | |
| Monoethanolamine SCHEMBL1263481 | 0.82 | — | — | |
| Glycine SCHEMBL9474283 | 0.82 | GLRA1 (0.83) | OR51E2GLRA1SLC6A9CA1CA2 | |
| Glycine SCHEMBL2150066 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108148112-B | Glycopeptide enrichment method based on amphiphilic porous core-shell microspheres | 中国科学院理化技术研究所 | 2020-09-18 | — | — | CN | disclosed |
| US-8492560-B2 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2013-07-23 | — | — | US | disclosed |
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | STOKES ELAINE S E (GB) | 2012-08-02 | — | — | US | disclosed |
| EP-2050744-A1 | Quinazoline derivatives as angiogenesis inhibitors | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| US-7135502-B1 | Colchinol derivatives as vascular damaging agents | ANGIOGENE PHARMACEUTICALS LTD. (GB) | 2006-11-14 | — | — | US | disclosed |
| US-7074800-B1 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2006-07-11 | — | — | US | disclosed |
| US-20060128633-A1 | Colchinol derivatives as vascular damaging agents | ANGIOGENE PHARMACEUTICALS LTD. | 2006-06-15 | — | — | US | disclosed |
| US-20060004017-A1 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB | 2006-01-05 | — | — | US | disclosed |
| US-20050277627-A1 | Colchinol derivatives as vascular damaging agents | ANGIOGENE PHARMACEUTICALS LIMITED (GB) | 2005-12-15 | — | — | US | disclosed |
| EP-1553097-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AND INTERMEDIATES THEREFORE | AstraZeneca AB (SE) | 2005-07-13 | — | — | EP | disclosed |
| WO-2000047212-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2000-08-17 | — | — | WO | disclosed |
| EP-1025088-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | AstraZeneca UK Limited (GB) | 2000-08-09 | — | — | EP | disclosed |
| WO-2000040529-A1 | COLCHINOL DERIVATIVES AS VASCULAR DAMAGING AGENTS | ANGIOGENE PHARMACEUTICALS LTD. (GB) | 2000-07-13 | — | — | WO | disclosed |
| WO-2000039716-A2 | ARYLPROPENYLIMIDAZOLES AS FARNESYL-PROTEIN TRANSFERASE INHIBITORS | ASTRAZENECA AB (SE) | 2000-07-06 | — | — | WO | disclosed |
| WO-1999020611-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | ZENECA LIMITED (GB) | 1999-04-29 | — | — | WO | disclosed |
| US-5371220-A | Bicyclo-heterocyclic intermediates for cephalosporin compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-12-06 | — | — | US | disclosed |
| EP-0304158-B1 | Cephalosporins, processes for their preparation and pharmaceutical compositions containing them | ICI PLC (GB) | 1994-06-22 | — | — | EP | disclosed |
| US-5232918-A | Bactericides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-08-03 | — | — | US | disclosed |
| US-5019570-A | Antibioics | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-05-28 | — | — | US | disclosed |
| EP-0304158-A1 | Cephalosporins, processes for their preparation and pharmaceutical compositions containing them | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128633-A1 | Colchinol derivatives as vascular damaging agents | NR1H3, NR1H2, NR1H4 | OR51E2 1626/4885GLRA1 1618/4885SLC6A9 4517/4885 |
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | VEGFA, FLT1, KDR | OR51E2 4814/4885GLRA1 3965/4885SLC6A9 438/4885 |
| US-20050277627-A1 | Colchinol derivatives as vascular damaging agents | TOP1, TDP1, TOP2B | OR51E2 4798/4885GLRA1 4786/4885SLC6A9 4348/4885 |
| US-20060004017-A1 | Quinazoline derivatives as angiogenesis inhibitors | FLT4, NOS3, FLT1 | OR51E2 3803/4885GLRA1 258/4885SLC6A9 2462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.